Terms: = Leukemia AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Prognosis
96 results:
1. Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities.
Roider T; Baertsch MA; Fitzgerald D; Vöhringer H; Brinkmann BJ; Czernilofsky F; Knoll M; Llaó-Cid L; Mathioudaki A; Faßbender B; Herbon M; Lautwein T; Bruch PM; Liebers N; Schürch CM; Passerini V; Seifert M; Brobeil A; Mechtersheimer G; Müller-Tidow C; Weigert O; Seiffert M; Nolan GP; Huber W; Dietrich S
Nat Cell Biol; 2024 Mar; 26(3):478-489. PubMed ID: 38379051
[TBL] [Abstract] [Full Text] [Related]
2. Genomic features reveal potential benefit of adding anti-pd-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma.
Chen Z; Huang H; Huang H; Yu L; Weng H; Xiao J; Zou L; Zhang H; Liang C; Zhou H; Guo H; Wang Z; Li Z; Wu T; Zhang H; Wu H; Peng Z; Zhai L; Chen X; Liang Y; Hong H; Lin T
Leukemia; 2024 Apr; 38(4):829-839. PubMed ID: 38378844
[TBL] [Abstract] [Full Text] [Related]
3. A murine model to evaluate immunotherapy effectiveness for human Fanconi anemia-mutated acute myeloid leukemia.
Huang T; Leung B; Huang Y; Price L; Gui J; Lau BW
PLoS One; 2024; 19(1):e0292375. PubMed ID: 38289944
[TBL] [Abstract] [Full Text] [Related]
4. CD8 + T cell-based molecular subtypes with heterogeneous immune landscapes and clinical significance in acute myeloid leukemia.
Zhong F; Yao F; Jiang J; Yu X; Liu J; Huang B; Wang X
Inflamm Res; 2024 Mar; 73(3):329-344. PubMed ID: 38195768
[TBL] [Abstract] [Full Text] [Related]
5. A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.
Bewersdorf JP; Shallis RM; Sharon E; Park S; Ramaswamy R; Roe CE; Irish JM; Caldwell A; Wei W; Yacoub A; Madanat YF; Zeidner JF; Altman JK; Odenike O; Yerrabothala S; Kovacsovics T; Podoltsev NA; Halene S; Little RF; Piekarz R; Gore SD; Kim TK; Zeidan AM
Ann Hematol; 2024 Jan; 103(1):105-116. PubMed ID: 38036712
[TBL] [Abstract] [Full Text] [Related]
6. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
7. Identification and validation of necroptosis-related gene signatures to predict clinical outcomes and therapeutic responses in acute myeloid leukemia.
Wen XM; Xu ZJ; Ma JC; Xia PH; Jin Y; Chen XY; Qian W; Lin J; Qian J
Aging (Albany NY); 2023 Nov; 15(24):14677-14702. PubMed ID: 37993258
[TBL] [Abstract] [Full Text] [Related]
8. The diagnostic/prognostic roles and biological function of the IFIT family members in acute myeloid leukemia.
Zhao Y; Zhang Y; Lu W; Sun R; Guo R; Cao X; Liu X; Lyu C; Zhao M
BMC Med Genomics; 2023 Nov; 16(1):296. PubMed ID: 37980495
[TBL] [Abstract] [Full Text] [Related]
9. CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma.
de Vos-Hillebrand L; Fietz S; Hillebrand P; Kulcsár Z; Diop MY; Hollick S; Maas AP; Strieth S; Landsberg J; Dietrich D
Pigment Cell Melanoma Res; 2024 Mar; 37(2):309-315. PubMed ID: 37975535
[TBL] [Abstract] [Full Text] [Related]
10. Higher pd-1/Tim-3 expression on IFN-γ+ T cells is associated with poor prognosis in patients with acute myeloid leukemia.
Huang S; Zhao Y; Lai W; Tan J; Zheng X; Zha X; Li Y; Chen S
Cancer Biol Ther; 2023 Dec; 24(1):2278229. PubMed ID: 37962843
[TBL] [Abstract] [Full Text] [Related]
11. Immune characteristics and prognostic implications of mucosal-associated invariant T cells in acute myeloid leukemia.
Peng Q; Huang R; Wang H; Xiao H; Wang Y; Zhai Z; Wang Z
Cancer Immunol Immunother; 2023 Dec; 72(12):4399-4414. PubMed ID: 37932426
[TBL] [Abstract] [Full Text] [Related]
12. Identification of cellular senescence-related signature for predicting prognosis and therapeutic response of acute myeloid leukemia.
Zhong F; Yang Y; Yao F; Liu J; Yu X; Wang XL; Huang B; Wang XZ
Aging (Albany NY); 2023 Oct; 15(20):11217-11226. PubMed ID: 37845004
[TBL] [Abstract] [Full Text] [Related]
13. Clinical implications of aberrant pd-1 expression for acute leukemia prognosis.
Ruan Y; Wang J; Zhang Q; Wang H; Li C; Xu X; Zhai Z
Eur J Med Res; 2023 Sep; 28(1):383. PubMed ID: 37759316
[TBL] [Abstract] [Full Text] [Related]
14. Accelerated Chronic Lymphocytic leukemia and Richter Transformation in the Era of Novel Agents.
Levy Yurkovski I; Tadmor T
Acta Haematol; 2024; 147(1):73-83. PubMed ID: 37666234
[TBL] [Abstract] [Full Text] [Related]
15. Determination of Cuproptosis-related Subtypes, Development of a Prognostic Model, and Characterization of Tumor Microenvironment Infiltration in Acute Myeloid leukemia.
Tao Y; Ren J; Xue T; Wang Y; Xu H; Zhang H; Lu J
Anticancer Res; 2023 Sep; 43(9):3943-3960. PubMed ID: 37648328
[TBL] [Abstract] [Full Text] [Related]
16. Immune checkpoint-related gene polymorphisms are associated with acute myeloid leukemia.
Wu Y; Li M; Meng G; Ma Y; Ye J; Sun T; Ji C
Cancer Med; 2023 Sep; 12(18):18588-18596. PubMed ID: 37602517
[TBL] [Abstract] [Full Text] [Related]
17. [Clinical Characteristics of Aggressive NK-Cell leukemia].
Liao Y; He HS; Wei YF; Shen DP; Ji XY; Huang C; Huang J; Jin XK; Huang DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):1026-1031. PubMed ID: 37551472
[TBL] [Abstract] [Full Text] [Related]
18. Pediatric T-cell acute lymphoblastic leukemia blast signature and MRD associated immune environment changes defined by single cell transcriptomics analysis.
Bhasin SS; Thomas BE; Summers RJ; Sarkar D; Mumme H; Pilcher W; Emam M; Raikar SS; Park SI; Castellino SM; Graham DK; Bhasin MK; DeRyckere D
Sci Rep; 2023 Aug; 13(1):12556. PubMed ID: 37532715
[TBL] [Abstract] [Full Text] [Related]
19. IGF2BP family of RNA-binding proteins regulate innate and adaptive immune responses in cancer cells and tumor microenvironment.
Elcheva IA; Gowda CP; Bogush D; Gornostaeva S; Fakhardo A; Sheth N; Kokolus KM; Sharma A; Dovat S; Uzun Y; Schell TD; Spiegelman VS
Front Immunol; 2023; 14():1224516. PubMed ID: 37503349
[TBL] [Abstract] [Full Text] [Related]
20. CD26
Zhou H; Jia B; Annageldiyev C; Minagawa K; Zhao C; Mineishi S; Ehmann WC; Naik SG; Cioccio J; Wirk B; Songdej N; Rakszawski KL; Nickolich MS; Shen J; Zheng H
Front Immunol; 2023; 14():1169144. PubMed ID: 37457737
[TBL] [Abstract] [Full Text] [Related]
[Next]
